Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
A patient with refractory CM showed the greatest improvement with a dual therapy of Botox and a CGRP receptor monoclonal antagonist antibody. By Houssein Salem-Abdou, MD, PhD, Pierre Naud, MD and Jack Puymirat, MD, PhD Pages 45-47 The prevalence of chronic migraine (CM) is estimated to be about 1.4% to 2.2% worldwide.1 Several preventive treatments are available for patients afflicted with this condition, including sodium valproate, topiramate, and propranolol.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
